Aripiprazole-Induced Oculogyric Crisis: A Pediatric Case Series and A Brief Narrative Review

Pia Bernardo 1, Alfonso Rubino 2, Claudia Santoro 3,4, Carmela Bravaccio 5, Marco Pozzi 6 and Simone Pisano 5,*

Abstract: Oculogyric crisis (OGC) represent an unusual type of dystonic movement disorder, usually reported as an adverse event of antipsychotic drugs, with acute or tardive onset, likely due to a functional disruption of dopaminergic neurotransmission. It is seldom reported in children with aripiprazole, an atypical antipsychotic commonly used in youths. In this manuscript, we report on a case series of three pediatric patients and provide a brief narrative review of the literature, in order to increase the awareness of clinicians and to foster future research in this area.

Keywords: aripiprazole; extrapyramidal effects; pediatric; oculogyric crisis

1. Introduction

Aripiprazole is an atypical antipsychotic often used in youths with tic disorders, psychosis spectrum disorder, bipolar disorder and irritability in the context of autism spectrum disorder. Within the group of atypical antipsychotics, aripiprazole shows a relatively benign safety profile (e.g., lower metabolic impact, mild effect on cardiovascular parameters) [1], although the reported rate of extrapyramidal side effects is substantial [2,3]. Pediatric populations may be more susceptible to aripiprazole-induced extrapyramidal symptoms (EPS) than adults because of differences in terms of pharmacokinetics, pharmacodynamics, and dopaminergic receptor density, which is inversely proportional to age [2]. However, in both pediatric and adult populations, the incidence of EPS can vary substantially, often depending on differences in antipsychotic dose.

Oculogyric crisis (OGC) is a rare movement disorder, characterized by a sustained, conjugate, usually upwards deviation of the eyes, lasting minutes to hours [4,5]. Originally described in subjects with postencephalitic Parkinsonism, OGCs have been recognized in association with several conditions as hereditary and sporadic movement disorders or focal brain lesions [5]. However, in most cases, OGC is a drug-induced adverse event with acute or tardive, yet abrupt, onset [6], typically attributable to a functional impairment of dopaminergic neurotransmission [5]. Antipsychotic drugs belong to the class mostly involved in causing OGC. OGCs are often accompanied by increased blinking of the eyes, ocular pain, backward and lateral flexions of the neck, blepharospasm, wide open mouth and tongue protrusion [7]. Psychiatric symptoms, or their exacerbation, may also occur during episodes of OGC [8,9]. OGC is seldom reported in children during
treatment with aripiprazole, although it is commonly used in youths. Herein, we report on three pediatric cases of OGC induced by aripiprazole and narratively review the existing literature (Table 1).

Table 1. Review of cases of aripiprazole-related OGC reported in the literature.

| Author                        | Sex/Age | Diagnosis                        | Clinical Features                                                                 | Associated Movement/Psychiatric Symptoms | Dose     | Duration of Treatment | Other Drugs                      | Management Strategy | Resolution (Y/N) |
|-------------------------------|---------|----------------------------------|----------------------------------------------------------------------------------|-----------------------------------------|----------|----------------------|----------------------------------|-------------------|------------------|
| Canol T et al., 2020          | F/14    | Bipolar disorder                 | Description: upward deviation of eyes and darting of vision                      | Frequency: 3-5 times in a day           | 15 mg    | 2 years              | Quetiapine 150 mg                 | Discontinued       | Y                |
| Moral et al., 2020            | M/19    | Obsessive compulsive disorder    | Description: up-rolling of the eyes and darting of vision                       | Frequency: 5-7 times in a day           | 10 mg    | <1 months            | Fluoxetine 80 mg                  | Switch to promethazine | Y                |
| Gharib DM et al., 2015        | F/22    | Schizophrenia, intellectual disability, in DiGeorge Syndrome | Description: disappearance of verbal function                                    | 30 mg                                   | <1 months (2 weeks) | No                  | Dose reduction to 20 mg, add on olanzapine | Y                |
| Gupta et al., 2014            | F/21    | Obsessive compulsive disorder    | Description: 7-8 episodes/day                                                     | Duration: 10 min                       | NA       | NA (new on other antipsychotics drugs) | Quetiapine and valporate          | Add on of nisup® formulation of niacin | Y                |
| Rizzo et al., 2012            | F/20    | Tourette syndrome                | Description: episodic deviation of eyes and darting of vision                    | Frequency: 1-5 episodes/mo Y            | 7.5 mg   | <1 months (6 days)   | Fluoxetine 1 mg/day               | Drug withdrawal       | Y                |
| Blachek JT et al., 2012       | F/28    | Paranoid schizophrenia           | Description: Appearance of multiple episodes of OGC                              | Duration: 1 month                       | NA       | NA                  | Add on of olanzapine              | Add on of olanzapine | N                |
| Lan HK et al., 2008           | M/25    | Down syndrome, ID, schizophrenia | Description: Appearance of multiple episodes of OGC                              | Duration: 1 month                       | 10 mg    | 9 months             | Yes                              | Y.                |
| Feontoulakis KN et al., 2006   | M/18    | Tourette syndrome                | Description: Appearance of multiple episodes of OGC                              | Duration: 1 month                       | 10 mg    | 9 months             | No                               | Add on of biperidone | Y                |

2. Case Presentations
2.1. Case 1

Patient Information

The first patient, a 13-year-old female, suffered from obsessive compulsive disorder (OCD) and anxiety disorder, with psychotic symptoms (persecutory ideas, visual hallucinations, marked social anxiety, states of psychomotor agitation). In her pharmacological anamnesis she had already taken several drugs, including lamotrigine and risperidone, which was discontinued for weight gain. Subsequently, she achieved good symptom control with valproic acid (VPA) 25 mg/kg/day, fluoxetine 20 mg/day and aripiprazole in association. Three months after an aripiprazole dose increase from 10 to 15 mg/day, she experienced a single episode of OGC, characterized by persistent upward deviation of the eyes, associated with pain and anxiety, profuse sweating, facial flushing, increase in obsessive thoughts and panic, lasting for 30–40 min approximately. A video-EEG and brain MRI were normal. After aripiprazole dose reduction to 10 mg/day, the patient presented no further episodes in the following 18 months, and her psychiatric symptoms were well controlled.
2.2. Case 2

Patient Information

The second patient, an 11-year-old male with ASD, treated with aripiprazole 10 mg/day, presented several episodes of OGC, characterized by gaze deviation up and right, and head deviation to the right. Episodes began one month after the introduction of aripiprazole, they lasted about 10 min each and had a frequency of two to three episodes per month, with spontaneous resolution. An EEG had been performed, showing no epileptiform abnormalities. Aripiprazole was reduced to 7.5 mg/day and the patient had no further episodes during the following 12 months.

2.3. Case 3

Patient Information

The third patient, a 14-year-old male, suffered from ASD and intellectual disability and began aripiprazole treatment for persistent and disabling irritability, emotional and behavioral dysregulation. He was taking VPA 20 mg/kg/day for a well-controlled focal occipital epilepsy. His EEG was stable, with epileptic abnormalities on the left occipital regions during sleep. The first OGC occurred around two weeks after increasing aripiprazole from 7 mg to the final titration step of 10 mg/day. The patient experienced upward deviation of the eyes, accompanied by eye pain, anxiety, headache and back head bending. An EEG and brain MRI were performed, showing no new abnormalities. Given a worsening in disruptive behaviors, he then gradually switched from aripiprazole to risperidone. After a few weeks he presented two more episodes of OGC. Trihexyphenidyl was added, and no episodes happened during six months of follow up.

2.4. Narrative Review

We searched non-systematically the English literature for “OGC and aripiprazole”, “OGC and antipsychotic”, “Ocular dystonia and aripiprazole” by using PubMed, Embase and Sciencegate. We identified ten articles describing eleven cases of OCG induced by aripiprazole (alone or in combination with other antipsychotics), summarized in Table 1. The subjects described were young adults (nine) or children (two). No specific psychiatric condition emerged as a determinant for the susceptibility to develop OGC. In addition, more than half of the cases showed other psychiatric symptoms or exacerbation of pre-existing symptoms in coincidence with episodes of OCG. In most subjects described, the OGCs had acute onset within 1 month of therapy initiation or up-titration. In one case, a subject with Down syndrome, OGC occurred 9 months after starting aripiprazole therapy [10]. Only in one case OCG occurred after more than 1 year of therapy. Furthermore, in this patient it was not sufficient to reduce the aripiprazole dosage, but discontinuation was necessary [11]. The OGCs were characterized by lifting or deviation of the eyes, lasting from 5 min to 2 h. Three of the subjects described also used other antipsychotics: olanzapine, risperidone, quetiapine [6,12,13]. In one pediatric case, aripiprazole was added to methylphenidate [14]. In two cases the onset of the OGC preceded the use of aripiprazole and occurred with olanzapine and paliperidone [13].

In all cases except one, the resolution of symptoms occurred after the discontinuation of aripiprazole and the adjunct of benzodiazepines or anticholinergics [15–18]. In one case, despite stopping all psychotropic medications for 3 months, recurrent episodes of OGC persisted for 7 months. The authors described this phenomenon as a long-lasting dystonia that included tardive and acute, persistent dystonia [13].

3. Discussion

We reported here three cases of OGC following treatment with aripiprazole in pediatric patients. We found a substantial phenomenological overlap with adult cases (>18 years), with the exception that, in our cases, OGCs happened without a previous exposure to another antipsychotic, thus excluding the possibility of a cumulative pharmacological
Two of our patients were on combined treatment with valproic acid and fluoxetine, but they are uncommonly associated with OGCs.

All our patients presented with OGC from a few weeks to several months after the initiation of aripiprazole, often after dose increase. The OGCs reported had the typical characteristics, such as ocular pain and upward gaze deviation, in all patients. In one patient, OGCs were also accompanied with “stereotypical paroxysmal psychiatric symptoms” with increase of anxiety, profuse sweating, face flushing, obsessive thoughts; another patient reported headache.

These clinical features underline how the differential diagnosis may be challenging, especially in the pediatric age group and in neurodevelopmental disorders, where a higher frequency of other movement disorders is observed, as compared to adults [2]. Indeed, ocular deviation movements must be evaluated critically during the diagnostic assessment, to rule out epileptic seizures, oculogyric tics as part of tic disorders, or clinical manifestations of neurometabolic disorders [5]. A thorough interview with caregivers, and, when possible, with the patient, prolonged observation possibly with video recording at home, and, when in doubt, a video EEG recording are useful tools to achieve a good diagnostic procedure.

Finally, in our small case series, while in the first two cases (1 and 2) there was a complete remission of the OGCs following aripiprazole dose reduction, suggesting the clinical manifestation was a dose-dependent phenomenon [2,10], in the last patient (3) we observed persistence of the dystonic episodes despite the switch to another second-generation antipsychotic drug. The persistence of OGC after discontinuation or switch to another antipsychotic drug has been previously reported [6,13,14], emphasizing the role of individual susceptibility, for example the hypothesized dopaminergic receptor density, as a substrate for developing OGCs.

The underlying pathophysiology of OCG is not adequately characterized; dopamine dysregulation with an hypodopaminergic state is likely a requirement. Aripiprazole acts as a partial antagonist on the mesolimbic pathway stimulating presynaptic D2 receptors reducing dopamine release and as a partial agonist on D2 at the postsynaptic level, producing limited effects on dopamine in the nigrostriatal pathway [19]. It has been supposed that this peculiar dopaminergic profile could be associated with a lower rate of EPS. However, considering that aripiprazole lacks anticholinergic effect and that evidence support an intrinsic activity of the drug consistent with a functional D2 striatal blockage, the incidence of EPS during treatment with aripiprazole is not negligible [20]. Therefore, aripiprazole-related OGCs must be considered within the frame of dystonic reaction, requiring an acute change in dopamine regulation of a previously intact system with a lack of presynaptic dopaminergic degeneration [4].

The present report should raise awareness among clinicians for this relevant possible adverse event, that may happen also with the use of aripiprazole in pediatric patients, not only with typical or more antidopaminergic antipsychotics. We highlight the intrinsic difficulty in obtaining a detailed evaluation of OGCs in patients with neurodevelopmental disorders. Future research in the field should emphasize neurobiological dysfunctions as the basis of EPS/OGC in younger patients, also using neurophysiological and neuroimaging diagnostic tools.

Author Contributions: Conceptualization, P.B. and A.R.; Data collection and assembly, P.B. and A.R. and S.P. Data analysis and interpretation, P.B., A.R. and M.P. Writing of manuscript, P.B., A.R., C.S. and M.P. Critical review and revision of manuscript, P.B., C.S., C.B., M.P. and S.P. Submission of manuscript, P.B. and S.P. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the Italian Ministry of Health (Ricerca Corrente, to MP) which is gratefully acknowledged. The funding public institution had no role in any part of the work.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Informed consent was obtained from all subjects involved.
Data Availability Statement: The data supporting the findings of this study are private due to patients’ privacy, but they are available from the corresponding author.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Pisano, S.; Catone, G.; Veltri, S.; Lanzara, V.; Pozzi, M.; Clementi, E.; Iuliano, R.; Riccio, M.P.; Radice, S.; Molteni, M.; et al. Update on the safety of second generation antipsychotics in youths: A call for collaboration among paediatricians and child psychiatrists. Ital. J. Pediatr. 2016, 42, 51. [CrossRef] [PubMed]
2. Bernagie, C.; Danckaerts, M.; Wampers, M.; De Hert, M. Aripiprazole and Acute Extrapyramidal Symptoms in Children and Adolescents: A Meta-Analysis. CNS Drugs 2016, 30, 807–818. [CrossRef] [PubMed]
3. Carbon, M.; Kapoor, S.; Sheridan, E.; Sarkaria, T.; Kane, J.M.; Saito, E.; Correll, C.U. Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment with 5 Second-Generation Antipsychotics. J. Am. Acad. Child. Adolesc. Psychiatry 2015, 54, 718–727. [CrossRef] [PubMed]
4. Slow, E.J.; Lang, A.E. Oculogyric crises: A review of phenomenology, etiology, pathogenesis, and treatment. Mov. Disord. 2017, 32, 193–202. [CrossRef]
5. Barow, E.; Schneider, S.A.; Bhatia, K.P.; Ganos, C. Oculogyric crises: Etiology, pathophysiology and therapeutic approaches. Parkinsonism Relat. Disord. 2017, 36, 3–9. [CrossRef]
6. Gardner, D.M.; Abidi, S.; Ursuliak, Z.; Morrison, J.; Teehan, M.D.; Tibbo, P.G. Incidence of Oculogyric Crisis and Long-Term Outcomes with Second-Generation Antipsychotics in a First-Episode Psychosis Program. J. Clin. Psychopharmacol. 2015, 35, 715–718. [CrossRef] [PubMed]
7. Solberg, M.; Koth, J. Oculogyric Crises. Tremor Other Hyperkinet. Mov. 2017, 7, 491. [CrossRef]
8. Praharaj, S.K.; Sarkhel, S.; Akhtar, S. Stereotyped paroxysmal psychiatric symptoms during oculogyric crisis or ‘cognitive dystonia’: A case report. Curr. Drug Saf. 2011, 6, 49–50. [CrossRef]
9. Thomas, N.; Sankar, S.S.; Braganza, D.; Jayakrishnan, S. Oculogyric crisis with exacerbation of psychosis: Possible mechanism and clinical implications. Neurosci. Lett. 2009, 451, 50–51. [CrossRef] [PubMed]
10. Lim, H.K.; Pae, C.U.; Lee, C.; Lee, C.U. Tardive dystonic symptoms associated with aripiprazole treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32, 589–590. [CrossRef] [PubMed]
11. Canol, T.; Sapmaz, S.Y.; Uzun, A.D.; Kandemir, H. Tardive Oculogyric Crisis due to Aripiprazole treatment in an adolescent patient diagnosed with Bipolar Disorder. Psychiatry Clin. Psychopharmacol. 2020, 30, 321–323. [CrossRef]
12. Fountoulakis, K.N.; Siamouli, M.; Kantartzis, S.; Panagiotidis, P.; Iacovides, A.; Kaprinis, G.S. Acute dystonia with low-dosage aripiprazole in Tourette’s disorder. Ann. Pharmacother. 2006, 40, 775–777. [CrossRef] [PubMed]
13. Gupta, R.; Balhara, Y.P. Antipsychotic induced chronic recurrent oculogyric crisis in a patient with obsessive compulsive disorder. Psycopharmacology 2014, 231, 3065–3066. [CrossRef] [PubMed]
14. Mercan Işık, C.; Demirci, B.; Sari, S.A.; Uzun, A. Aripiprazole-induced oculogyric crisis (acute dystonia) in 11 years old girl: A case report. Cumhur. Med. J. 2020, 42, 403–406. [CrossRef]
15. Bhachech, J.T. Aripiprazole-induced oculogyric crisis (acute dystonia). J. Pharmacol. Pharmacother. 2012, 3, 279–281. [CrossRef] [PubMed]
16. Rizzo, R.; Gulisano, M.; Calì, P.V. Oculogyric crisis: A rare extrapyramidal side effect in the treatment of Tourette syndrome. Eur. Child. Adolesc. Psychiatry 2012, 21, 591–592. [CrossRef] [PubMed]
17. Nebhinani, N.; Suthar, N. Oculogyric crisis with atypical antipsychotics: A case series. Indian J. Psychiatry 2017, 59, 499–501. [CrossRef] [PubMed]
18. Suthar, N.; Nebhinani, N. Aripiprazole induced neck dystonia and oculogyric crisis. Asian J. Psychiatry 2018, 31, 94–95. [CrossRef] [PubMed]
19. Burris, K.D.; Molski, T.F.; Xu, C.; Ryan, E.; Tottori, K.; Kikuchi, T.; Yocca, F.D.; Molinoff, P.B. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J. Pharmacol. Exp. Ther. 2002, 302, 381–389. [CrossRef] [PubMed]
20. Etminan, M.; Procyslyn, R.M.; Samii, A.; Carleton, B.C. Risk of Extrapyramidal Adverse Events with Aripiprazole. J. Clin. Psychopharmacol. 2016, 36, 472–474. [CrossRef] [PubMed]